Oxopicolinamide Derivative FXIa Inhibitor Bleeding Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticoagulant drugs targeting FXa or thrombin have significant side effects, particularly bleeding risks, and existing FXIa inhibitors, such as antisense oligonucleotides, have slow onset of action and limited preventive effects.
Innovation Solution
Development of novel small molecule FXIa antagonists with a specific oxopyridinyl amide derivative structure, offering improved anticoagulant efficacy and pharmacokinetic properties for treating and preventing cardiovascular and cerebrovascular diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional anticoagulant drugs (warfarin, heparin, FXa inhibitors, thrombin inhibitors) are used, then thrombosis prevention effect is improved, but bleeding risk increases significantly
Solution Approach 1:
The patent extracts and targets a specific enzyme (FXIa) in the coagulation cascade that is less critical for maintaining normal hemostasis compared to other factors. By selectively inhibiting FXIa rather than broadly affecting multiple coagulation factors, the drug prevents thrombosis while minimizing activation of alternative coagulation pathways that would lead to bleeding complications.
Solution Approach 2:
The invention applies local quality by designing a highly selective FXIa inhibitor that acts specifically at one targeted site in the coagulation cascade. The compound structure is optimized to bind selectively to FXIa's active site, providing localized inhibition precisely where needed to prevent pathological coagulation without disrupting other essential coagulation functions.
2Reliability
If antisense oligonucleotides (ASO) targeting FXI are used, then FXIa inhibitory effect is achieved, but onset of action is slow and preventive effect is limited
Solution Approach 1:
The patent replaces the mechanical/biological process of ASO-mediated gene silencing (which requires transcription and translation inhibition over days) with a direct small molecule enzyme inhibitor that acts immediately upon administration. The small molecule compound directly binds to FXIa's active site, providing rapid pharmacological inhibition without requiring genomic or proteomic changes.
Solution Approach 2:
The invention creates a simplified copy or mimic of the natural substrate that FXIa acts upon. The small molecule compound is designed to resemble the natural peptide substrate, allowing it to bind to and inhibit FXIa directly, providing immediate effect rather than requiring the complex cellular processes needed for ASO mechanisms.
3Adaptability or versatility
If existing FXIa inhibitors are developed, then anticoagulant specificity is improved, but pharmacokinetic properties and efficacy need enhancement
Solution Approach 1:
The patent employs composite material principles by combining multiple structural features in the small molecule compound: a core heterocyclic structure with specific functional groups positioned to interact with key residues in FXIa's binding site. This composite molecular structure achieves both high specificity through multiple interaction points and high efficacy through optimized binding affinity and pharmacokinetic properties.
Solution Approach 2:
The invention applies parameter changes by systematically optimizing molecular parameters of the small molecule compound including molecular weight, lipophilicity, hydrogen bonding capacity, and structural rigidity. These parameter optimizations enhance both the specificity for FXIa and the pharmacokinetic properties such as absorption, distribution, metabolism, and excretion, thereby improving overall anticoagulant efficacy.
Data Source
AI summary
The present invention relates to an oxopicolinamide derivative, a preparation method therefor and the pharmaceutical use thereof. In particular, the present invention relates to the oxopicolinamide derivative as shown in the general formula (AI), a preparation method therefor and a pharmaceutical composition comprising the derivative, and to the use thereof as a therapeutic agent, in particular as an inhibitor of blood coagulation factor XIa (Factor XIa, FXIa for short) and the use thereof in the preparation of a drug for treating diseases such as thromboembolism, wherein the definition of each substituent in the general formula (AI) is the same as defined in the description.